Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

被引：0
|
作者：
Moshe C. Ornstein
Laura S. Wood
机构：
[1] Cleveland Clinic,Hematology and Medical Oncology
[2] Cleveland Clinic,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adverse event; Axitinib; Combination; First-line; Immune checkpoint inhibitor; Renal cell carcinoma; Therapy management;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3599 / 3609
页数：10
相关论文
共 50 条
  • [1] Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
    Ornstein, Moshe C.
    Wood, Laura S.
    ADVANCES IN THERAPY, 2023, 40 (09) : 3599 - 3609
  • [2] Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
    Moshe C. Ornstein
    Laura S. Wood
    Advances in Therapy, 2023, 40 : 4116 - 4116
  • [3] Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib plus Checkpoint Inhibitor
    Zakharia, Yousef
    Huynh, Lynn
    Du, Shawn
    Chang, Rose
    Pi, Selina
    Sundaresan, Sanjana
    Duh, Mei S.
    Zanotti, Giovanni
    Thomaidou, Despina
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : E343 - E351
  • [4] Axitinib as first-line therapy in metastatic renal cell carcinoma
    Nozawa, Masahiro
    Uemura, Hirotsugu
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 555 - 557
  • [5] First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review
    Thana, Myuran
    Wood, Lori Anne
    KIDNEY CANCER, 2020, 4 (02) : 81 - 92
  • [6] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [7] Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review
    Petrelli, Fausto
    Vavassori, Ivano
    Rossitto, Mauro
    Dottorini, Lorenzo
    CANCERS, 2024, 16 (14)
  • [8] Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era
    Numakura, Kazuyuki
    Muto, Yumin
    Naito, Sei
    Hatakeyama, Shingo
    Kato, Renpei
    Koguchi, Tomoyuki
    Kojima, Takahiro
    Kawasaki, Yoshihide
    Kandori, Syuya
    Kawamura, Sadafumi
    Arai, Yoichi
    Ito, Akihiro
    Nishiyama, Hiroyuki
    Kojima, Yoshiyuki
    Obara, Wataru
    Ohyama, Chikara
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    CANCER MEDICINE, 2021, 10 (17): : 5839 - 5846
  • [9] CLINIC AND HOME BLOOD PRESSURE MEASUREMENTS ARE RELIABLE FOR GUIDING THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING AXITINIB AS FIRST-LINE THERAPY
    Gruenwald, V.
    Fishman, M. N.
    Carducci, M.
    Bair, A.
    Chen, Y.
    Kim, S.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 268 - 268
  • [10] The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma
    Kameda, Tomohiro
    Takayama, Tatsuya
    Sugihara, Toru
    Takeshima, Saki
    Yamazaki, Masahiro
    Komatsubara, Maiko
    Kamei, Jun
    Fujisaki, Akira
    Ando, Satoshi
    Kurokawa, Shinsuke
    Fujimura, Tetsuya
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) : 241 - 246
12345